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Abstract: Palladium-based compounds are regarded as potential analogs to platinum anticancer
drugs with improved properties. The present study assessed the pharmacokinetics and biodistri-
bution of a dinuclear palladium(II)-spermine chelate (Pd2Spm), which has previously been shown
to possess promising in vitro activity against several therapy-resistant cancers. Using inductively
coupled plasma-mass spectrometry, the kinetic profiles of palladium/platinum in serum, serum
ultrafiltrate and tissues (kidney, liver, brain, heart, lungs, ovaries, adipose tissue and mammary
glands) were studied in healthy female Balb/c mice after a single intraperitoneal bolus injection of
Pd2Spm (3 mg/kg bw) or cisplatin (3.5 mg/kg bw) between 0.5 and 48 h post-injection. Palladium in
serum exhibited biphasic kinetics with a terminal half-life of 20.7 h, while the free palladium in serum
ultrafiltrate showed a higher terminal half-life than platinum (35.5 versus 31.5 h). Palladium was
distributed throughout most of the tissues except for the brain, with the highest values in the kidney,
followed by the liver, lungs, ovaries, adipose tissue and mammary glands. The in vitro cellular accu-
mulation was also evaluated in breast cancer cells, evidencing a passive diffusion as a mechanism
of Pd2Spm’s cellular entry. This study reports, for the first time, the favorable pharmacokinetics
and biodistribution of Pd2Spm, which may become a promising pharmacological agent for cancer
treatment.
Keywords: Pd(II)-based drugs; cisplatin; ICP-MS; metal complexes; polyamines; cancer; tissue;
in vivo
1. Introduction
The discovery of the anticancer properties of the platinum(II)-based drug cisplatin
(cis-Pt(NH3)2Cl2) (Figure 1a) has revolutionized the therapy of solid neoplasms, namely,
breast, testicular, ovarian, cervical, prostate, head, neck, bladder and lung cancers, as well
as refractory non-Hodgkin’s lymphoma [1]. However, its therapeutic use is limited by
inherent or acquired tumor cell resistance and dose-dependent toxicity (namely, nephrotox-
icity, hepatotoxicity, neurotoxicity and myelosuppression). To overcome these limitations,
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several modifications of cisplatin’s structure have led to the development of carboplatin
and oxaliplatin, which have also received worldwide approval for clinical use. Carbo-
platin (Figure 1b) is a 2nd generation platinum drug with an improved pharmacokinetic
profile and tolerability, owing to the substitution of the two chloride ligands by a cyclobu-
tanedicarboxylate group that has a slower hydrolysis rate to yield reactive species prone
to bind to DNA [2]. Carboplatin is indicated in a monotherapy regimen of ovarian and
small cell lung carcinomas, but it shares a cross-resistance with cisplatin in previously
cisplatin-treated patients, which limits its clinical use [3]. Oxaliplatin (Figure 1c) is a 3rd
generation platinum analog with a diaminocyclohexane ligand that significantly reduces its
toxicity and glutathione-mediated acquired tumor cell resistance [4]. Although oxaliplatin
is less reactive towards DNA than cisplatin, it was demonstrated in vitro that its crosslinks
appear to be more damaging [5]. Currently, oxaliplatin in combination with 5-fluorouracil
is approved for the treatment of advanced colorectal cancer.
The pharmacodynamic effects of cisplatin and other platinum agents are generally
accepted to be mediated by the binding to DNA in the nucleus and mitochondria, while
other non-DNA targets, such as RNA, tubulin, thioredoxin reductase, membrane-bound
Na+/H+ exchanger protein [6], or even intracellular water [7], have also been reported.
Upon cellular entry, the drug’s hydrolyzable ligands are substituted with water molecules,
yielding highly reactive aqua species that bind to DNA (mainly through the purine’s
nitrogen atoms) [8]. The formation of these drug-DNA adducts prompts DNA damage,
which interferes with the replication and transcription processes and leads to cell growth
impairment and cellular death [2].
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Figure 1. Structure of Pt(II)- and Pd(II)-based agents: orld ide approved Pt drugs (a) cisplatin, (b) carboplatin and
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Despite the indisputable role of mononuclear platinum drugs (compounds with one
metal center, such as cisplatin, carboplatin and oxaliplatin) in the therapy of solid neo-
plasms, there is considerable interest in the development of more ffic ent metal-based
anti umor agents that could surpass the drawbacks of conventional platinum drugs while
presenting a broader therapeutic spectrum coupled to low toxic ty [9]. Even though from
the thermodynamic point of view, a Pt-ligand bond in conventional platinum(II) coordina-
tion compounds presents somewhat lower thermodynamic durability (100 kJ/mol) than
single and double c va nt bonds between C–C, C–N or O (250–500 kJ/mol), the ligand
substitution is ra her slow, yielding reasonably stable molecules with desired n vivo phar-
mac kinetic nd pharm codyn ic properties [10,11]. In addition to numerous platinum
compo nds developed in recent decad s [9], complexes containing other transiti n metals
have also been investigated, including palladium(II) [12], gold(I), gold(II), tin(IV) [13],
ruthenium(II), ruthenium(III) [14] and copper(II)-based compoun s [15]. Palladium(II)
complexes have received particular interest as potential Pt(II) analogs thanks to the simi-
larities in structure and coordination chemistry between these t o metal ions [12,16]. As
observed for Pt coordination compounds, a successful substitution of the central atom for
Pd(II) should be closely related to the nature of its ligands (including leaving groups) in
order to provide suitable thermodynamic and kinetic features: thermodynamic stability
coupled to low kinetic lability (to avoid instantaneous ligand exchange). In particular,
biogenic polyamines, such as spermidine (H2N(CH2)4NH(CH2)3NH2, Spd) and spermine
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(H2N(CH2)3NH(CH2)4NH(CH2)3NH2, Spm), have been identified as suitable chelating
ligands for both Pt and Pd-metal ions, allowing the formation of stable chelates with ap-
propriate kinetic properties [17]. For instance, the dinuclear Pd(II) complex with spermine
as a bridging ligand (Pd2Spm, Figure 1d) has shown promising in vitro anticancer activity
against osteosarcoma [18], breast [19,20] and ovarian cancers [21]. Pd2Spm’s antineoplastic
activity is attributed to unconventional DNA interactions at more than one site in the dou-
ble helix via the formation of long-range interstrand adducts that trigger more severe and
less repairable cell damage than the clinically used mononuclear Pt(II) compounds (e.g.,
cisplatin) [17,22,23]. Additionally, Pd-based compounds are expected to display higher
tolerability and safety profiles than conventional Pt-based drugs [24,25], which warrants
their further in vivo investigation.
Despite the promising studies that have already reported on the anticancer prop-
erties of Pd(II)-agents, information on their pharmacokinetic profile, including in vivo
biodistribution, is scarce. To the best of the authors￿ knowledge, the preclinical assays of
padeliporfin (approved in 2017 for the vascular-targeted photodynamic therapy of prostate
cancer) [26,27] constitute the only in vivo pharmacokinetic study of a Pd(II)-compound
carried out to date. However, this agent has been designed to exert local pharmacological
effect only upon activation with a specific wavelength laser light, which produces reactive
oxygen species in the target area. Therefore, its utility for the pharmacokinetic compar-
isons to Pd2Spm is limited. The present work aimed to provide insights into the in vivo
pharmacokinetics and biodistribution of a dinuclear Pd(II)-spermine complex (Pd2Spm)
as compared to the mononuclear Pt(II) drug cisplatin. Additionally, due to the promising
anticancer activity of Pd2Spm towards triple-negative breast cancer cells (as previously
reported by the authors [19,20]), the in vitro cellular uptake of Pd2Spm and cisplatin in
triple-negative breast cancer cells was also assessed to address the differences in intra-
cellular accumulation of these two compounds. The amount of total Pd or Pt in cancer
cells and biologic samples (serum, serum ultrafiltrate, kidney, liver, brain, heart, lungs,
ovaries, mammary glands and white adipose tissue) was determined by inductively cou-
pled plasma-mass spectrometry (ICP-MS), which enables highly sensitive measurements
of metal-based compounds (both the parent compound and its metabolites).
2. Results
2.1. Drug Pharmacokinetics in Serum and Serum Ultrafiltrate
The concentrations of Pd and Pt in serum (total Pd/Pt) and serum ultrafiltrate (free
Pd/Pt) after a single intraperitoneal bolus injection of Pd2Spm 3 mg/kg or cisplatin
3.5 mg/kg, in healthy female Balb/c mice, were measured by ICP-MS, the corresponding
pharmacokinetic parameters obtained with non-compartmental analysis being summarized
in Table 1. The serum concentration–time profiles of Pd (from Pd2Spm) and Pt (from
cisplatin) are shown in Figure 2. The decrease in Pd and Pt concentrations in serum and
serum ultrafiltrate showed a biphasic kinetic behavior with a rapid initial distribution
phase followed by a prolonged first-order elimination phase in both Pd2Spm- and cisplatin-
treated animals (see Figure 2). Since the maximum concentration (cmax) for both Pd and
Pt in plasma was reached immediately at the first sampling time-point, 0.5 h, the Pd/Pt
concentration during the preceding period (<30 min post-injection) may be higher.
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Table 1. Pharmacokinetic parameters of total Pd and Pt in serum and serum ultrafiltrate following intraperitoneal bolus




Total Pd in Serum Free Pd in Ultrafiltrate Total Pt in Serum Free Pt in Ultrafiltrate
Half-life (h) 20.7 35.5 43.3 31.5
 z (1/h) 0.034 0.019 0.016 0.022
Tmax (h) 0.5 0.5 0.5 0.5
Cmax (ng/mL) 1499.4 ± 38.5 749.0 ± 120.6 1009.6 ± 64.2 350.7 ± 16.8
Cmax/Dose (ng/mL/µg) 65.9 ± 4.2 32.7 ± 5.3 21.9 ± 1.9 7.7 ± 0.4
AUC0–48 h (h ⇥ ng/mL) 6490.2 1219.7 10867.5 567.2
AUC0–48 h/Dose
(h ⇥ ng/mL/µg) 285.0 53.2 240.5 12.5
AUC0–• (h ⇥ ng/mL) 7523.9 1339.1 19,758.5 751.5
Vz/F (mL/kg) 4555.0 43,992.0 7202.8 143,864.7
CL/F (mL/h/kg) 152.8 858.8 115.4 2989.9
 z = elimination rate constant; Tmax = time to reach Cmax; Cmax = mean maximum concentration ± SEM; AUC0 48 h = area under curve
from time zero to 48 h; AUC0 • = area under the curve from time zero to infinity; Vz/F = volume of distribution at terminal phase; CL/F =
body clearance.
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Figure 2. Kinetic profiles of Pd (from Pd2Spm, 3 g/kg bw) and Pt (from cisplatin, 3.5 mg/kg bw) in serum and serum
ultrafiltrate after single intraperitoneal bolus injection in Balb/c mice. Data are expressed as mean ± SEM (n = 5 animals per
time point). (a) Concentration–time plot of mean Pd or Pt levels in serum and serum ultrafiltrate. (b) Concentration–time
plot of mean Pd or Pt levels in serum and serum ultrafiltrate normalized to administered metal dose.
Pd2Spm administration (3 mg/kg bw) resulted in mean serum Pd concentrations
within the range of 34.7 to 1499.4 ng/mL. The maximum concentration (Cmax),
1499.4 ± 38.5 ng/mL, declined rapidly within the first hour and decreased steadily during
the terminal elimination phase. In serum, Pd was found to display an elimination half-life
of 20.7 h and a clearance (CL/F) of 152.8 mL/h/kg. Its volume of distribution (Vz/F:
4555.0 mL/kg) in mice was greater than total body water, suggesting the widespread distri-
bution of Pd in tissues. Free Pd reached Cmax = 749.0 ± 120.6 ng/mL, with an elimination
half-life of 35.5 h and CL/F = 858.8 mL/h/kg. At 48 h, the concentration of free Pd in
serum ultrafiltrate was 2.3 ng/mL.
Administration of cisplatin (3.5 mg/k ) resulted in mean serum Pt concentrations
within t e range 142.4 to 1009.6 ng/mL. The Cmax 1009.6 ± 4.2 ng/mL decreased teadily
with a terminal half-li e of 43.3 h and a CL/ 115.4 mL/h/kg. The volume of dis-
tribution was 7202.8 mL/kg. Fre Pt in serum peaked at a aximum concentration of
Cmax = 350.7 ± 16.8 ng/mL, with an elimination half-life of 31.5 h, a volume of distribution
equal to 143,864.7 mL/kg and CL/F = 2989.9 mL/h/kg. At 48 h, the concentration of free
Pt was found to be 4.1 ng/mL.
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Even though the doses of Pd2Spm (3 mg/kg) and cisplatin (3.5 mg/kg) used in this
study were somewhat similar, the actual dose of Pd administered to the animals was only
half of the dose of Pt owing to the difference in the metal composition in each compound
(dinuclear versus mononuclear in Pd2Spm and cisplatin, respectively; please see Section 4.8,
for further clarification). Therefore, to obtain biologically meaningful comparisons of rela-
tive metal kinetics, the mean Pd and Pt concentrations were normalized to the administered
metal dose (Figure 2b). Regarding the metal dose-normalized concentration–time profiles
in serum ultrafiltrate, a higher concentration of free Pd than Pt was found during the
0.5–12 h period, reaching equivalent concentrations for both metals during the 24–48 h
period. The dose normalization also revealed that animals treated with Pd2Spm reached a
3- and a 4.2-fold higher Cmax in serum and serum ultrafiltrate, respectively, compared to
cisplatin. Additionally, considering the dose-normalized areas under the curve (AUCs),
Pd2Spm administration resulted in a 1.2- (p > 0.05) and a 4.3-fold (p < 0.001) higher AUC
for Pd in serum and serum ultrafiltrate when compared to cisplatin, respectively.
2.2. Drug Binding to Plasma Proteins
The analysis of Pd and Pt concentrations in serum ultrafiltrate showed different
profiles of plasma protein binding. At 0.5 and 1 h following Pd2Spm administration, only
ca. 50% of Pd from Pd2Spm was bound to plasma proteins and 91.0% at 6 h, reaching the
maximum protein plasma binding of 95.9% at 12 h post-administration (Figure 3). At 48 h,
92.8% of Pd2Spm was bound to plasma proteins. For cisplatin, in turn, a faster binding was
determined—65.5% at 0.5 h and 89.5% at 1 h, reaching a maximum of ca. 97% at 6 h (i.e.,
virtually twice as fast relative to Pd2Spm). A comparative analysis revealed significantly
lower Pd binding (from Pd2Spm) to plasma proteins than Pt (from cisplatin) during the
0.5–6 h period after drug administration. Additionally, while at 12 and 24 h, Pd and Pt
showed similar binding to plasma proteins (ca. 96–97%), at 48 h, the fraction of Pd bound
to plasma proteins presented a 3.1% decrease compared to the preceding period.
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Figure 3. Drug binding to plasma proteins versus time, for cisplatin and Pd2Spm. Data are expressed
as mean ± SEM (n = 5 animals per time point) and were compared with Student’s t-test. * p < 0.05,
** p < 0.01, *** p < 0.001.
2.3. Drug Tissue Biodistribution
Accumulation of Pd (from Pd2Spm) and Pt (from cisplatin) in mice kidney, liver, lungs,
heart, adipose tissue, mammary gland, brain and ovaries was determined by ICP-MS,
and the corresponding AUC0–48 h for each tissue is presented in Figure 4a. Except for the
brain, Pd was widely distributed in the tested tissues, and the primary accumulation was
found in the kidney, followed by the liver, lungs, ovaries, adipose tissue and ammary
glands. Excluding the kidney, the animals treated with a single cisplatin dose showed
a higher accumulation of Pt in all the organs than the Pd levels found in the organs of
Pd2Spm-treated animals. In the kidney, similar Pd and Pt concentrations were found (when
comparing cisplatin- and Pd2Spm-treated mice), suggesting a similar accumulation of
Pharmaceuticals 2021, 14, 173 6 of 16
metals in renal tissue when doses of 3 mg/kg of Pd2Spm and 3.5 mg/kg of cisplatin are
administered. The corresponding kinetic profiles of Pd and Pt concentrations in tissues are
also available in Appendix B—Figure A1. Since these metal concentrations at 12 h post-
administration of either drug—Pd2Spm (Figure A1a) or cisplatin (Figure A1b) did not show
a substantial decrease during the sampling period of 48 h, the pharmacokinetic parameters
for each tissue could not be estimated. The normalization of AUCs to the administered
metal dose evidenced 1.7- and 1.4-fold higher exposures to Pd versus Pt in kidney and
adipose tissues, respectively, suggesting a higher relative accumulation of Pd2Spm. In turn,
the dose-normalized AUCs for Pd in liver, lungs, heart, ovaries and mammary tissue were
lower compared to Pt exposure; Pd was decreased by 43.9% in liver, 68.4% in lungs, 73%
in heart, 44.1% in mammary tissue and 59.4% in ovaries as compared to Pt. The brain
was the least exposed studied tissue, evidencing 82.7% lower accumulation of Pd than
Pt, which indicates a reduced permeability of the blood–brain barrier to Pd2Spm than to
cisplatin. The dose-normalized kinetic profiles for Pd (Figure A2a) and Pt (Figure A2b) in
mice tissues are available in Appendix B.
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2.4. I Vitro Cellular Drug Uptake
Since Pd2Spm has already shown promising in vitro anticancer activity against sev-
eral cisplatin-resista t cancers [19,28], the in vitro cellular uptake/accumulation of either
Pd2Spm r cisplatin in triple-negative breast cancer cells—MDA-MB-231 (from pleural
metastasis of breast carcinoma) and HCC-1143 (fro inva ive ductal breast carc oma)—
was also eval ated by ICP-MS. The results of Pd2Spm or cisplatin accumulat on n c lls
treated with equimola drug concentrations (between 2 and 8 µM) are depicted in Figure 5
and evidenced a lower intrace lular Pd2Spm increase as compared to cisplatin for both
MDA-MB-231 and HCC-1143 cells (Figure 5a,b, respectively). This cellular drug uptake
was shown to increase linearly with drug concentration in the cell culture medium, suggest-
ing passive transport as the primary mechanism of cellular uptake for the two compounds.
Interestingly, a higher accumulation of Pd2Spm (and cisplatin) was observed in HCC-1143
cells relative to MDA-MB-231 cells.
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3. Discussion
In the present study, the pharmacokinetics and biodistribution of Pd(II)-spermine
chelate Pd2Spm were investigated after a single intraperitoneal bolus injection in Balb/c
mice. Biphasic kinetics was observed upon the administration of Pd2Spm (3 mg/kg), with
similar pharmacokinetics and tissue biodistribution patterns to those of the reference drug,
cisplatin. Cisplatin’s pharmacokinetics (at a 3.5 mg/kg dose) was determined in parallel,
with the results agreeing with previously published studies [29–31].
Even though the terminal half-life of Pd (from Pd2Spm) in serum was found to be
20.7 h, in contrast with 40.3 h for Pt (from cisplatin), the free Pd in serum ultrafiltrate had a
higher terminal half-life than Pt (35.5 versus 31.5 h, respectively), which suggests a longer
persistence of free Pd in blood circulation during the terminal elimination phase. The
analysis of serum ultrafiltrate has particular relevance since this biological matrix contains
free drug and its low molecular weight metabolite(s) (<30 kDa in this study prepared
with a cut-off 30K NMWL filter), which are both responsible for exerting pharmacological
effects [32]. Upon systemic administration, the drug occurs in plasma in different forms:
(i) as a free, intact molecule administered in vivo; (ii) free hydrolyzed species and/or low
molecular weight etabolites; and (iii) a plas a protein-bound drug (either via reversible
or irreversible bonds with different affinities and kinetics). The drug binding to plasma
proteins (namely, albumin, ↵1-acid glycoprotein and lipoproteins) is an unavoidable effect
that influenc s the pharmacokinetic and pharmacodynamic pro erti s of all systemically
administered drugs. In gen ral, a drug’s high binding to plasma proteins results in the
drug’s lo er tissue er ilit , a s all l f i i i , metabolism,
l ra ce and prolonged half-life. In turn, considering the widely accepted free
drug theory, the concentration of the free drug in las a c rr l tes r curately with
the drug’s pharmacological effects and toxic ty than the to al plasma concentration (free
drug plus protein-bound drug), as only the fr e drug is able to reach its target in tissues
and exert therap utic effects. The free drug theory als stipulates that when a steady-state
equilibrium s reached in t e plasma, the free drug concentratio in plasma reflects the
pharmacologically relevant amount of the free drug at the arge site (i.e., tissues) [33].
Regarding conventional Pt(II)-agents (cisplatin, carboplatin and oxaliplatin), previous
in vivo studies in rodents have shown different interactions of these drugs with plasma
proteins; at 3 h post-administration, >85% of cisplatin and oxaliplatin were bound to
albumin mostly via irreversible covalent bonds, while only 20% to 50% of carboplatin was
reversibly bound to plasma proteins [34–36]. Indeed, Pt-based chemotherapeutics undergo
both aquation reactions and biologic transformation in blood, which allow the binding of
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a drug’s metal center to cysteine and methionine residues of amino acids that constitute
plasma proteins (mostly via covalent bonds that inactivate platinum agents) [37]. This
process is highly time-dependent and differs between different platinum drugs, depending
on the stability of its ligands and leaving groups [38]. In the present work, the analysis of
serum ultrafiltrate samples showed that at 1 h post-administration, only ca. 50% of Pd2Spm
was bound to plasma proteins compared to ca. 90% for cisplatin, revealing different
affinities of Pd2Spm and cisplatin towards plasma proteins. Since most cisplatin is bound
to plasma proteins via irreversible bonds, only a small fraction of administered cisplatin
is available to cross cell membranes and exert pharmacological effects. Pd2Spm, on the
other hand, showed a lower affinity to coordinate to plasma proteins, which indicates
that following administration, the majority of Pd2Spm is initially present in the plasma
as a free unbound drug, which may more easily reach its targets in the tissues and exert
pharmacological effects. These results are further supported with 4.3-fold (p < 0.001)
higher AUC and longer elimination half-life (35.5 h) of free Pd in serum ultrafiltrate, which
suggests a higher availability and persistence of free Pd than free Pt in blood circulation.
Concerning the drug’s in vivo biodistribution, both Pd2Spm and cisplatin showed a
similar pattern in the five major organs analyzed (brain, lungs, heart, liver and kidney).
The highest exposure to Pd and Pt was observed in the kidney, followed by the liver,
lungs, heart and brain, with the latter being the least exposed organ. However, despite the
similar affinity for accumulation in specific organs, the comparative analysis of relative
metal amount in tissues (measured as metal dose-normalized AUC) revealed a significantly
lower exposure to Pd in the liver, lungs, heart and brain as compared to Pt. Therefore,
owing to its limited accumulation, Pd2Spm is expected to be well tolerated, without
noteworthy deleterious effects in these organs. Additionally, our data suggest that the
low accumulation of Pd in the brain may be explained by the very low permeability of
the blood–brain barrier to Pd2Spm; thus, this agent is highly unlikely to affect the central
nervous system. In turn, a 74.2% higher accumulation of Pd (from Pd2Spm) relative
to Pt (from cisplatin) was determined in the kidney. This very large disparity in the
accumulation of Pd and Pt in the kidney compared to the other organs was an expected
outcome, which agrees with previous reports for several Pt-based compounds [39–41]. The
dose-dependent nephrotoxicity of Pt-based drugs results from the binding of the drug’s
Pt center to thiol-containing renal enzymes (e.g., metallothioneins) [24] but, as shown
for oxaliplatin and carboplatin, which displayed a higher and lower renal accumulation
than cisplatin, respectively [42], the total content of Pt accumulated in the kidney is an
unreliable biomarker of nephrotoxicity, and attention should be paid to specific interactions
between the drug/its metabolites and renal biomolecules likely to be responsible for
functional deviation and associated toxicity [36,42,43]. Several authors have anticipated
lower nephrotoxicity elicited by Pd-based compounds owing to their decreased reactivity
towards sulfhydryl groups of proteins in the kidney; however, it still remains to be fully
understood under in vivo conditions [25,44]. Accordingly, since we observed the highest
exposure to Pd2Spm (and cisplatin) in the kidney and liver, the metabolic impact of Pd2Spm
and cisplatin on these organs had already been the subject of our parallel work aiming to
determine possible deleterious alterations [45,46]. Using an identical experimental design,
the metabolomics results evidenced that Pd2Spm treatment triggered rapid and short-
term changes with almost complete recovery to control levels in the liver (both polar and
lipid metabolites) and kidney (polar metabolites), while cisplatin induced distinctive and
more persistent deviations [45]. In general, these metabolic results provided encouraging
evidence that Pd2Spm treatment may induce lower negative effects compared to the
treatment with cisplatin [46], despite considerable Pd accumulation in the kidney and liver.
Finally, the comparative study of the cellular uptake of either Pd2Spm or cisplatin in
MDA-MB-231 and HCC-1143 breast cancer cells showed that the in vitro accumulation
of these drugs within the 2 to 8 µM range increases linearly with concentration and
appears to follow Fick’s law for passive diffusion. Interestingly, a higher accumulation of
Pd2Spm (as well as of cisplatin) was observed in HCC-1143 cells relative to MDA-MB-231
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cells, which is consistent with the putative occurrence of different uptake mechanisms for
these two types of cell lines, which may also differ in the cell membrane composition, as
previously reported for several breast cancer cell lines [47]. While a lower intracellular
uptake of Pd2Spm was observed compared to cisplatin, Pd2Spm has been reported to
cause more extensive phosphorylation of H2AX histone ( H2AX) [28], which is an indirect
measure of DNA breaks induced by metalation of the nucleic acid. This result is in
agreement with previously reported data on the mode of action of this polynuclear agent—
Pd2Spm is able to bind to DNA via unconventional, long-range crosslinks, which are
more deleterious than conventional interactions (e.g., cisplatin-prompted), particularly
towards fast-growing malignant cells [17,22,23]. A similar discrepancy between desired
pharmacologic effects and cellular uptake has been recently reported for conventional
Pt-based agents—cisplatin, carboplatin and oxaliplatin [5]. This study by Schoch and co-
workers (2020) showed that carboplatin shares a mechanism of action with cisplatin, while
oxaliplatin acts differently: the former led to identical DNA lesions (and a comparable
gene response), and the latter exhibited similar cytotoxicity to cisplatin, despite its lower
intracellular accumulation [5]. Therefore, since Pd2Spm showed linear accumulation in
breast cancer cells coupled to favorable pharmacokinetic and biodistribution properties, this
study provides an encouraging basis for further in vivo studies focused on the anticancer
properties of Pd2Spm. While the current study provides valuable findings regarding the
pharmacokinetics and biodistribution of Pd (from Pd2Spm) in serum, serum ultrafiltrate
and tissues, the excretion/metabolism of Pd2Spm was not addressed in this work and will
be investigated in future research.
4. Materials and Methods
4.1. Reagents and Chemicals
Polypropylene 10 mL tubes with high-density polyethylene screw caps (Ref# 62.9924.284)
used for sample digestions were from Sarstedt (Nümbrecht, Germany). Nitric acid (HNO3,
TraceSELECT™,  69.0%) and hydrochloric acid (HCl, TraceSELECT™,  30%) were pur-
chased from Honeywell Fluka™ (Düsseldorf, Germany). For ICP-MS determinations,
the multi-element standard solution TraceCERT® (100 mg/L), ICH Q3D oral, Standard
2 solution from Merck KGaA (Darmstadt, Germany) and the internal standard solution
ICP-MS-200.8-IS-1 (100 mg/L of Sc, Y, In, Tb, Bi) from AccuStandard® (New Haven, CT,
USA) were used. Ultrapure water (18.2 MW.cm at 25  C) was obtained with an Arium®
pro water purification system (Sartorius, Goettingen, Germany). Animals were eutha-
nized with Euthasol® solution (400 mg/mL pentobarbital sodium) acquired from Le Vet
(Oudewater, The Netherlands). Cisplatin (cis-dichlorodiammine platinum(II), 99.9%),
potassium tetrachloropalladate (II) (K2PdCl4, 98%), spermine (N,N’-bis(3-aminopropyl)-
1,4-diaminobutane, 99%), DMEM-HG cell culture medium and RPMI-1640 cell culture
medium were purchased from Sigma-Aldrich (Sintra, Portugal). Fetal bovine serum (FBS)
was from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). All the other reagents
were of analytical grade.
4.2. Cell Culture
The in vitro studies were performed on human triple-negative (lack of estrogen re-
ceptors, progesterone receptors and HER2 overexpression) breast cancer cell lines MDA-
MB-231 and HCC-1143, which were purchased from the Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures GmbH, Germany. MDA-MB-231 were
cultured in DMEM-HG cell culture medium supplemented with 10% (v/v) FBS, and HCC-
1143 cells were cultured in RPMI-1640 cell culture medium supplemented with 20% (v/v)
FBS. Cells were maintained in a sterile environment at 37  C with a 5% CO2 humidified
atmosphere and were routinely tested for mycoplasma contamination.
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4.3. Ethical Considerations
The European Directive 2010/63/EU on the protection of laboratory animals used for
scientific purposes (European Parliament, Council of the European Union, 2010) and the
Portuguese law on animal welfare (Decreto-Lei 113/2013) were followed for designing
and conducting all research procedures. The study protocol was approved by the Ethics
Committee of the Faculty of Pharmacy of the University of Porto, Porto, Portugal (Permit
Number: 25-10-2015), and by the Ethics Committee and the Organ Responsible for the
Welfare of Animals of ICBAS-UP, Porto, Portugal (Permit number 134/2015). All sections
of this study follow the ARRIVE Guidelines for reporting animal research [48].
4.4. Animals
Six-week old, Specific-Pathogen-Free (SPF), female BALB/cByJ mice (60 animals in
total) were purchased from Charles River Laboratories (L’Arbresle, France) and acclima-
tized at ICBAS-UP Rodent Animal House Facility (Porto, Portugal) for one week. Animals
were randomly distributed into groups of five per individually ventilated cage and were
housed under controlled SPF environmental conditions (temperature 22.5 ± 1.5  C; relative
humidity 50 ± 10%; 12 h light/dark cycle) with ad libitum access to water and standard
pellet food (4RF21, Mucedola, Italy). Environmental enrichment included corncob bedding,
paper roll tube and one large sheet of tissue paper for nesting. Animals were monitored
daily for health status, and no adverse events were observed during the study.
4.5. Pd2Spm Synthesis and Formulation
Pd2Spm complex was synthesized according to published procedures [49] optimized
by the authors [50]: 2 mmol of K2PdCl4 was dissolved in a minimal amount of water, and 1
mmol of spermine aqueous solution was added dropwise under continuous stirring. After
24 h, the resulting orange powder was filtered, washed with acetone, and yellow-orange
needle-shaped crystals were recrystallized from water. The composition and purity of
synthesized compound were fully characterized by elemental analysis and vibrational
spectroscopy (FTIR, Raman and inelastic neutron scattering), which were compared with
the previously calculated vibrational profiles (by ab initio methods) [50,51]. Yield: 68%.
Elemental analysis (Pd2(C10N4H26)Cl4): found—C: 21.2%; H: 4.7%; N: 9.6%, Cl: 25.9%;
calculated—C: 21.5%; H: 4.6%; N: 9.9%, Cl: 25.6%. Pd2Spm 0.3 mg/mL solution for in vivo
administration was freshly prepared by dissolving an appropriate quantity of drug in
Phosphate-Buffered Saline (PBS) (H2PO4 1.5 mM, Na2HPO4 4.3 mM, KCl 2.7 mM, NaCl
150 mM, pH 7.4) containing 1% of DMSO and sterile-filtered. The solution of cisplatin
0.35 mg/mL was prepared in PBS and sterile-filtered.
4.6. Pharmacokinetic Study Design and Sample Collection
Animals were randomly allocated into two study groups (30 animals/group): Pd2Spm
and cisplatin. No control group was used since Pt and Pd metals were inexistent in
drug-naïve rodents. On the day of the experiments, animals were weighed (mean ± SD:
20.4 ± 1.7 g), and a single dose of Pd2Spm 3 mg/kg BW (corresponds to 1.15 mg/kg BW of
Pd) or cisplatin 3.5 mg/kg BW (corresponds to 2.28 mg/kg BW of Pt) was administered
via intraperitoneal bolus injection (200 µL/injection) in Pd2Spm and cisplatin groups,
respectively. After drug administration, five animals from each group were euthanized at
selected time-points (0.5, 1, 6, 12, 24 and 48 h) with pentobarbital intraperitoneal injection
(120 mg/kg) followed by cardiac puncture for blood collection. Blood serum was separated
after leaving the blood to coagulate for 30 min at room temperature and centrifugation (at
500⇥ g, and 4  C for 15 min). The serum was separated, and a small aliquot was filtered
using Amicon Ultra-0.5 mL Centrifugal Filters (14,000⇥ g, 20  C, 30 min) with 30K NMWL
(Merck KGaA, Darmstadt, Germany) to obtain serum ultrafiltrate for the study of drug
binding to plasma proteins. Both blood serum and serum ultrafiltrate were aliquoted
(50 µL) and stored at  80  C until ICP-MS analysis. Right brain hemisphere, liver, lungs,
heart, right kidney, ovaries, abdominal white adipose tissue and abdominal mammary
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glands were excised at the same time, washed in cold PBS, blotted dry on filter paper
and weighed. Solid tissues were freeze-dried (0.016 mBar,  80.8  C, 48 h; Telstar®, model
Cryodos Barcelona, Spain) and stored hermetically sealed at  80  C until ICP-MS analysis.
The complete characterization of the study groups with the respective body and wet tissue
weights are available in Appendix A—Figure A1.
4.7. Sample Preparation and ICP-MS Analysis
Quantification of Pd and Pt in the biologic samples collected from in vivo pharma-
cokinetic studies was achieved using a validated method previously developed by our
group [52]. Briefly, 50 µL of blood serum, 50 µL of serum ultrafiltrate and weighed entire
freeze-dried organs/tissues (up to 50 mg) were placed into 10 mL polypropylene conical
tubes. In the case of liver, for which the weight surpassed 50 mg, the tissue was first
pulverized with a Precellys® Evolution tissue homogenizer (Bertin-Instruments, Montigny-
le-Bretonneux, France) using 2.8 mm stainless steel beads (two cycles of 10 s at 6000 rpm
speed) and accurately weighed (50 mg) in tubes. Samples were digested directly in tubes
with 0.9 mL of HNO3 ( 69.0% w/w) plus 0.3 mL of HCl (37% w/w) in a water bath at
90  C for 1 h. Sample digests were cooled to room temperature, 0.5 mL of a 100 µg/L
internal standards (IS) solution was added and the final volume was adjusted to 5 mL with
ultrapure water (final concentration of IS = 10 µg/L). Prior to ICP-MS analysis, samples
were further diluted 5-fold with a diluent solution (2% HNO3 + 3% HCl + 10 µg/L IS). An
iCAPTM Q (Thermo Fisher Scientific, Bremen, Germany) ICP-MS was used for the determi-
nation of Pd and Pt in the obtained solutions. Calibration standards ranging from 0.025 to
100 µg/L were prepared from the 100 mg/L multi-element commercial TraceCERT®, ICH
Q3D oral, Standard 2 solution. The IS solution was prepared at 100 µg/L by appropriate
dilution of the ICP-MS-200.8-IS-1 solution. The elemental isotopes (m/z ratios) 108Pd and
195Pt were used for analytical determination. 89Y, 115In, 159Tb and 209Bi were used as
internal standards.
4.8. Pharmacokinetic Analysis
Pharmacokinetic parameters for Pd2Spm and cisplatin were estimated using Phoenix
WinNonlin v8.3.1.5014 (Certara USA Inc., Princeton, NJ, USA). The data were expressed
as nanograms of Pd (from Pd2Spm) or Pt (from cisplatin) measured by ICP-MS per gram
of wet tissue weight or per mL of serum/serum ultrafiltrate. Considering the molecular
weights of each compound and the molar ratios of respective atoms, the molar ratio of Pd
atom in Pd2Spm molecule is 2:1 with mass Pd (%) = 38.21%, [MW(Pd2Spm) = 557 g/mol];
and the molar ratio of Pt atom in cisplatin molecule is 1:1 with mass Pt (%) = 65.02%,
[MW(cisplatin) = 300.01 g/mol]. Accordingly, the administered dose of Pd (from Pd2Spm
3 mg/kg) was 1.15 mg/kg, and the administered dose of Pt (from cisplatin 3.5 mg/kg) was
2.28 mg/kg. The mean concentrations of Pd or Pt in serum and serum ultrafiltrate were
plotted logarithmically versus time. Non-compartmental analysis was performed on sparse
data with 1/Y2 weighting, which was selected based on the highest correlation coefficients
and agreement between observed versus predicted pharmacokinetic parameters. The
highest drug concentration observed following administration (Cmax) and the time at
which it was observed (tmax) were established from the temporal evolution of respective
Pd/Pt concentrations in serum and serum ultrafiltrate. The area under the curve (AUC)
from time zero to the last time with quantified concentration (AUC0-48h) was calculated by
a linear log trapezoidal (linear up log down) method. The AUC from time zero to infinity
(AUC0 •) was extrapolated as AUC0 48 h + C48h/ z, where C48h is the last measured
concentration, and  z is the elimination constant rate calculated using linear regression
of the terminal portion of the log–linear serum concentration–time curve. The drug half-
life (t1/2) was calculated as ln2/ z. The rate of total clearance (CL/F) of the compound
was calculated as the administered metal dose divided by the AUC0 •. The distribution
volume based on the terminal phase (Vz/F) was calculated as dose/[ z.AUC0 •].
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4.9. Intracellular Accumulation of Pd2Spm or Cisplatin in Breast Cancer Cells
The intracellular Pt and Pd accumulation in MDA-MB-231 and HCC-1143 cells was
analyzed using ICP-MS. First, 3 ⇥ 104/cm2 cells were seeded in T75 culture flasks and
allowed to attach for 24 h. Cells were subsequently treated for 24 h with 2, 4 or 8 µM
of either Pd2Spm or cisplatin in four independent experiments (n = 4). The cells were
trypsinized, washed twice with ice-cold 0.9% saline solution, and 106 cells were pelleted
and freeze-dried. The lyophilized cell pellets were digested and analyzed using the same
analytical procedure described for the pharmacokinetic study. The quantity of accumulated
Pd and Pt in cells was converted in the correspondent concentration of Pd2Spm and
Cisplatin in pmoles per 1 mg of protein. The protein concentration used for the data
normalization was determined from identical samples that were prepared in parallel and
quantified with the Bradford protein assay.
4.10. Statistical Analysis
Data are expressed as the mean ± standard error of the mean (SEM) and compared
with a two-tailed Student’s t-test, using GraphPad Prism 7 Software (San Diego, CA, USA).
A p-value < 0.05 was considered statistically significant.
5. Conclusions
Altogether, this work reported, for the first time, an in vivo pharmacokinetic study of a
dinuclear Pd(II)-polyamine anticancer agent (Pd2Spm) after intraperitoneal bolus injection
in healthy Balb/c mice. Using ICP-MS, the tissue biodistribution and several pharmacoki-
netic parameters were obtained and compared with those measured for cisplatin, taken
as a reference drug. Furthermore, the in vitro cellular uptake/accumulation of Pd2Spm
and cisplatin in triple-negative breast cancer MDA-MB-231 and HCC-1143 cells was also
carried out to assess the differences in the transport mechanism and cellular accumulation
of these two compounds.
Pd2Spm showed appropriate pharmacokinetics regarding its potential therapeutic
application. In addition, it displayed a slower plasma protein binding and a higher terminal
half-life of free Pd in serum as compared to cisplatin. Since the overall accumulation of
Pd in tissues was lower than Pt (in Pd2Spm- and cisplatin-treated mice, respectively), it is
expected that Pd(II)-agent might present decreased systemic adverse effects. Additionally,
the in vitro assays evidenced an increase in the drug’s intracellular concentration with the
applied dose, which implies a passive diffusion as a primary mechanism of cellular entry.
In short, this study provides valuable insights into i) the in vivo pharmacokinetic profile
and biodistribution of Pd2Spm and ii) the in vitro intracellular uptake/accumulation in
triple-negative breast cancer cells, allowing further research and preclinical development
of this promising compound. In addition, the results thus gathered constitute a reliable
scientific basis for future pharmacokinetics studies of other Pd-based potential anticancer
agents.
Author Contributions: Conceptualization, M.V., S.G.-M., M.P.M.M., H.M.-F., I.M.P.L.V.O.F. and C.D.;
methodology (synthesis and characterization of Pd2Spm), A.L.M.B.d.C. and C.B.M.; methodology
(pharmacokinetics), M.V., S.G.-M., E.P. and A.A.; validation, M.V. and E.P.; formal analysis, M.V.;
investigation, M.V., S.G.-M., E.P. and S.K.; data curation, M.V.; writing—original draft preparation,
M.V., M.P.M.M. and C.D.; writing—review and editing, all authors; visualization, M.V.; supervision,
M.P.M.M., H.M.-F., I.M.P.L.V.O.F. and C.D.; project administration, M.P.M.M., I.M.P.L.V.O.F. and
C.D.; funding acquisition, M.P.M.M., I.M.P.L.V.O.F. and C.D. All authors have read and agreed to the
published version of the manuscript.
Funding: This work received financial support from PT national funds (FCT/MCTES, Fundação
para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior) through the
project UIDB/50006/2020 and UIDB/00070/2020. Martin Vojtek thanks the Portuguese Foundation
for Science and Technology (FCT) and PhD Program in Medicines and Pharmaceutical Innovation
(i3DU) for PhD Grant PD/BD/135460/2017 funded by the European Social Fund of the European
Union and national funds FCT/MCTES. FCT is also acknowledged for PTDC/QEQ-MED/1890/2014,
Pharmaceuticals 2021, 14, 173 13 of 16
(within Project 3599—to Promote Scientific Production and Technological Development as well as the
formation of thematic networks (3599-PPCDT)—jointly financed by the European Community Fund
FEDER).
Institutional Review Board Statement: The study was approved by the Ethics Committee of the
Faculty of Pharmacy of the University of Porto, Porto, Portugal (Permit Number: 25-10-2015), and by
the Ethics Committee and the Organ Responsible for the Welfare of Animals of ICBAS-UP, Porto,
Portugal (Permit number 134/2015).
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Acknowledgments: Authors thank Sara Capas-Peneda for procedural support and valuable recom-
mendations during the in vivo experiments. We thank Joana B. Sousa, Maria do Céu Pereira, Mónica
Caldas and João S. Marques for their help during tissue collection and sample processing. We also
kindly thank Anabela Costa for technical assistance.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A


















Ciplatin 0.5 20.6 ± 2.3 157.7 ± 19.4 962.3 ± 120.8 192.5 ± 31.5 110.9 ± 10.6 182.8 ± 28.0 101.8 ± 44.0 110.8 ± 31.1
1 20.0 ± 1.6 151.8 ± 23.4 765.8 ± 378.5 159.0 ± 32.9 99.5 ± 7.6 178.0 ± 29.4 95.0 ± 46.7 81.5 ± 37.1
6 19.6 ± 0.9 140.4 ± 10.1 824.5 ± 144.3 197.1 ± 7.2 104.8 ± 7.5 188.9 ± 22.3 86.6 ± 30.9 100.3 ± 45.3
12 20.0 ± 2.1 156.3 ± 20.2 878.3 ± 224.3 184.3 ± 23.5 114.4 ± 19.0 166.9 ± 34.9 93.8 ± 32.1 105.3 ± 44.4
24 19.8 ± 1.5 153.6 ± 14.9 824.5 ± 155.8 173.0 ± 21.1 109.6 ± 5.6 183.3 ± 22.8 87.9 ± 28.5 95.0 ± 46.4
48 19.8 ± 2.0 149.3 ± 20.2 939.7 ± 137.0 166.1 ± 17.2 107.6 ± 8.9 195.7 ± 24.6 79.3 ± 16.9 116.8 ± 21.2
Pd2Spm 0.5 21.2 ± 1.3 160.9 ± 11.2 897.9 ± 199.2 188.8 ± 16.8 113.4 ± 8.1 200.7 ± 31.7 82.6 ± 12.9 119.0 ± 12.4
1 22.2 ± 1.1 161.2 ± 7.2 1034.4 ± 89.6 187.9 ± 27.8 117.0 ± 7.0 191.5 ± 20.7 87.7 ± 12.3 119.0 ± 18,6
6 21.0 ± 1.2 153.3 ± 12.6 1056.8 ± 264.3 188.3 ± 18.9 112.7 ± 12.0 212.8 ± 23.4 86.8 ± 14.2 115.0 ± 23.3
12 19.6 ± 2.2 148.9 ± 14.4 1010.1 ± 196.4 188.4 ± 11.9 105.3 ± 7.9 179.8 ± 18.7 89.3 ± 20.8 88.1 ± 21.7
24 20.6 ± 1.1 168.4 ± 14.8 868.8 ± 76.0 190.6 ± 19.8 115.9 ± 0.4 190.1 ± 11.4 63.1 ± 17.3 83.0 ± 27.9
48 20.6 ± 0.9 154.4 ± 6.3 983.9 ± 279.7 197.1 ± 21.0 105.5 ± 6.1 203.1 ± 24.6 68.6 ± 8.0 87.7 ± 26.3
Data are means of five animals per time point ± standard deviation (n = 5/time point).
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Figure A1. Kinetic profiles of Pd (from Pd2Spm, 3 mg/kg bw) and Pt (from cisplatin, 3.5 mg/kg bw) in tissues after single 
intraperitoneal bolus injection in Balb/c mice. Data are expressed as mean ± SEM (n = 5 animals per time point). Units: 




Figure A2. Metal dose-normalized kinetic profiles of Pd (from Pd2Spm, 3 mg/kg bw) and Pt (from cisplatin, 3.5 mg/kg bw) 
in tissues after single intraperitoneal bolus injection in Balb/c mice. Data are expressed as mean ± SEM (n = 5 animals per 
time point). Units: h.ng/g per µg metal dose (a) Concentration–time plot of mean Pd levels (normalized to administered 
metal dose) in tissues. (b) Concentration–time plot of mean Pt levels (normalized to administered metal dose) in tissues. 
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